Zheng Ya-Shang, Lin Wu-Hao, Chen Jun-Quan, Wei Xiao-Li, Huang Jia-Qian, Xu Yu-Hong, Yang Meng, Zhang Qi-Hua, Zuo Zhi-Jun, Yang Zhao-Ying, Zhang Pan, Hong Nga Ki, Liu Lu-Xuan, Zeng Zhao-Lei, Xu Rui-Hua, Luo Hui-Yan
Department of Medical Oncology State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Provincial Clinical Research Center for Cancer Sun Yat-Sen University Cancer Center Guangzhou People's Republic of China.
Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer Chinese Academy of Medical Sciences Guangzhou People's Republic of China.
MedComm (2020). 2025 Aug 11;6(8):e70316. doi: 10.1002/mco2.70316. eCollection 2025 Aug.
Immunotherapy has revolutionized the treatment of gastrointestinal (GI) cancers, but reliable biomarkers for predicting treatment efficacy remain limited. In this study, we explored the potential of blood microbiome and specific microbial taxa as novel biomarkers for predicting the efficacy of immunotherapy combined with chemotherapy in GI cancer patients through 16S rRNA sequencing. Our findings demonstrated that lower baseline alpha diversity and specific microbial compositions, particularly lower levels of , were significantly associated with longer progression-free survival (PFS) in patients receiving immunotherapy combined with chemotherapy. Furthermore, we validated the reliability of abundance as a predictor of PFS and treatment response in another independent patient cohort. Additionally, patients with increased or stable levels of after immunotherapy combined with chemotherapy had superior PFS. Gavage of el evated its blood level and enhanced the efficacy of immunotherapy in mouse models. Our results suggest that may serve as a novel biomarker for predicting the efficacy of immunotherapy combined with chemotherapy and hold the potential as a PD-1 antibody sensitizer.
免疫疗法已经彻底改变了胃肠道（GI）癌症的治疗方式，但用于预测治疗效果的可靠生物标志物仍然有限。在本研究中，我们通过16S rRNA测序探索了血液微生物组和特定微生物分类群作为预测GI癌症患者免疫疗法联合化疗疗效的新型生物标志物的潜力。我们的研究结果表明，较低的基线α多样性和特定的微生物组成，特别是较低水平的 ，与接受免疫疗法联合化疗的患者更长的无进展生存期（PFS）显著相关。此外，我们在另一个独立的患者队列中验证了 丰度作为PFS和治疗反应预测指标的可靠性。此外，免疫疗法联合化疗后 水平升高或稳定的患者具有更好的PFS。在小鼠模型中，灌胃 可提高其血液水平并增强免疫疗法的疗效。我们的结果表明， 可能作为预测免疫疗法联合化疗疗效的新型生物标志物，并具有作为PD-1抗体增敏剂的潜力。
